logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

An Important Reminder from Vir Biotechnology

Vir Biotechnology  Vir Biotechnology ( VIR ) is a commercial-stage immunology firm focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir assembled four technology platforms that stimulate and enhance the immune system by exploiting...

Read More

May 19, 2022

0

Gilead Sciences and Merck Initiate Phase 2 Study Evaluating Lenacapavir and Islatravir for HIV-1

Gilead Sciences and Merck Collaboration to Develop Long-Acting HIV Treatment  Gilead Sciences ( GILD ) and Merck ( MRK ) announced the start of a Phase 2 clinical study evaluating an investigational, once-weekly oral combination treatment regimen of islatravir and...

Read More

October 26, 2021

0

Pfizer and BioNTech Vaccine Candidate Against COVID-19 Achieved a Sweet Success

Pfizer and BioNTech Good News Regarding COVID-19 Vaccine Candidate Pfizer ( PFE ) and BioNTech ( BNTX ) announced that their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 (the virus that causes COVID-19) has demonstrated evidence of efficacy against COVID-19 in...

Read More

November 9, 2020

0

Vertex Pharmaceuticals and Type 1 Diabetes

Vertex Pharmaceuticals to Announce New Data on VX-880 Clinical Trial Vertex Pharmaceuticals ( VRTX ) announced three abstracts, including two oral presentations and one poster, detailing data on type 1 diabetes ( T1D ) and its Phase 1/2 trial of...

Read More

May 31, 2022

0

No Evidence of Data Manipulation in Technical Paper Foundational to Cassava Sciences Lead Drug Candidate

Cassava Science: Journal of Neuroscience Review Shows No Evidence of Data Manipulation Cassava Sciences ( SAVA ) has been informed by the  Journal of Neuroscience that there is no evidence of data manipulation in an article it published in July 2012...

Read More

November 4, 2021

0

Moderna's Future Growth

Moderna Inc COVID-19 Vaccine Candidate Moderna Inc ( MRNA ) announced the completion of the case accrual for the first interim analysis of Phase 3 COVE study of mRNA-1273, its COVID-19 vaccine candidate. The firm announced a significant increase in...

Read More

November 12, 2020

0

Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at ASH

Intellia Therapeutics to Present at ASH Intellia Therapeutics ( NTLA ) announced the presentation of data from its ex vivo research and development efforts in two poster presentations at the 63rd American Society of Hematology ( ASH ) Annual Meeting and Exposition taking place...

Read More

November 6, 2021

0

Moderna's Successful COVID-19 Vaccine Results

Moderna Has Successful COVID-19 Vaccine Results and News Moderna’s Phase 3 study met statistical criteria with a vaccine efficacy of 94.5%. Moderna intends to submit for an Emergency Use Authorization (EUA) with U.S. FDA in the coming weeks and expects...

Read More

November 16, 2020

0

Insilico Medicine: Identifying Multiple Novel Therapeutic Targets for ALS AI-driven Target Discovery Engine

Insilico Medicine Insilico Medicine is a clinical stage end-to-end artificial intelligence ( AI )-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models,...

Read More

July 7, 2022

0

CytomX Therapeutics Provided an Important Strategic Update

CytomX Therapeutics Update CytomX Therapeutics ( CTMX ) announced plans to focus on its emerging preclinical and early clinical pipeline and realign its capital resources to drive these efforts. Sean McCarthy, D.Phil. Chief Executive Officer and Chairman, CytomX Therapeutics, said,...

Read More

July 14, 2022

0

  • Previous
  • 1
  • 2
  • ...
  • 100
  • 101
  • 102
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy